Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

John Radcliffe Oxford University Hospital is the First Medical Center in the UK to Use VEST Technology in Patients Undergoing Coronary Bypass Surgery

Vascular Grafts Solution
Posted on: 01 Aug 18
John Radcliffe Oxford University Hospital is the First Medical Center in the UK to Use VEST Technology in Patients Undergoing Coronary Bypass Surgery

PR Newswire

TEL AVIV, Israel, Aug. 1, 2018

TEL AVIV, Israel, Aug. 1, 2018 /PRNewswire/ -- Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery.

"After several decades in which little progress had been made in coronary bypass surgery, we are now experiencing several exciting developments in the field," said Prof. David Taggart, Professor of Cardiovascular Surgery at Oxford University and consultant cardiac surgeon at the John Radcliffe Hospital. "Recent major trials have ended the long standing debate regarding the relevance of bypass surgery in the era of less invasive treatment options and concluded that bypass surgery remains the best treatment option for patients with severe coronary disease."

Prof. Taggart continues: "Performing state of the art bypass surgery and advancing clinical research is our commitment to patients. This means not only using the most advanced surgical techniques such as multi arterial grafting and off pump surgery, but also employing technologies that have the potential to substantially improve the quality and outcomes of surgery and to minimize patients' discomfort."

"I would like to thank the team in Oxford for their major contribution to the field of bypass surgery," said Dr. Eyal Orion, founder and CEO of Vascular Graft Solutions. "In the last seven years, the team at John Radcliffe hospital, under the direction of Prof. Taggart, led four major trials that evaluated our technology including the first in human trial in 2011. This partnership between surgeons, nurses, scientists and engineers is based on our mutual vision to develop new treatments with significant benefit to patients' lives. To date, VEST technology has being used successfully in thousands of patients globally. We are glad that it became available for patients in the UK and we are looking forward to working with Prof. Taggart and his team on our future projects."

About VGS

VGS is a privately held company based in Tel Aviv, Israel. The company develops novel solutions for cardiac and vascular surgeries. VEST is a novel external support for saphenous vein grafts in coronary bypass procedures. VEST is CE marked and was implanted successfully in more than 2,000 patients and is commercialized in several countries.

www.graftsolutions.com

Contact:
Rotem Katzenellenbogen
VP Business Development
Rotem@graftsolutions.com 
+972-3-5499054

* Disclosure: Prof Taggart would emphasize that VGS have funded his research, provided travelling and speaking honoraria and has share options in VGS

 

View original content with multimedia:http://www.prnewswire.com/news-releases/john-radcliffe-oxford-university-hospital-is-the-first-medical-center-in-the-uk-to-use-vest-technology-in-patients-undergoing-coronary-bypass-surgery-300690177.html

SOURCE Vascular Grafts Solution

PR Newswire
www.prnewswire.com

Last updated on: 01/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.